Identification of a novel point mutation in ENT1 that confers resistance to Ara‐C in human T cell leukemia CCRF‐CEM cells | Zendy

Zimmerman Eric I. | Zendy; Huang Min | Zendy; Leisewitz Andrea V. | Zendy; Wang Yanhong | Zendy; Yang Jing | Zendy; Graves Lee M. | Zendy

Premium

Identification of a novel point mutation in ENT1 that confers resistance to Ara‐C in human T cell leukemia CCRF‐CEM cells

Author(s) -

Zimmerman Eric I.,

Huang Min,

Leisewitz Andrea V.,

Wang Yanhong,

Yang Jing,

Graves Lee M.

Publication year - 2009

Publication title -

febs letters

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.593

H-Index - 257

eISSN - 1873-3468

pISSN - 0014-5793

DOI - 10.1016/j.febslet.2008.12.041

Subject(s) - nucleoside , missense mutation , mutant , point mutation , mutation , chemistry , arginine , biochemistry , microbiology and biotechnology , biology , gene , amino acid

The genetic basis for the Ara‐C resistance of CCRF‐CEM Ara‐C/8C leukemia cells was investigated. DNA sequencing revealed that these cells expressed an equilibrative nucleoside transporter 1 (ENT1) with a single missense mutation resulting in glycine to arginine replacement (G24R). To test the importance of this residue, additional G24 mutants were created and examined for [3H]‐uridine and [3H]‐Ara‐C uptake. Both a G24E and G24A mutant showed reduced ENT1‐dependent activity. An EGFP‐tagged G24R ENT1 displayed plasma membrane localization even though it was unable to bind [3H]‐NBMPR, an ENT1‐specific inhibitor. These results define G24 as critical amino acid for ENT1 nucleoside uptake and suggest that mutations in TM1 may provide a mechanism for Ara‐C resistance in CCRF‐CEM Ara‐C/8C cells.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research